Cathepsin inhibitors for treating microglia-mediated neuron loss in the central nervous system

A technology of glial cells and neurons, applied in the field of cathepsin inhibitors for the treatment of microglial cell-mediated neuronal loss in the central nervous system

Inactive Publication Date: 2014-09-10
VIROBAY INC
View PDF9 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, abnormal activity of cysteine ​​proteases, e.g. due to increased expression or activation, can lead to pathological consequences

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Cathepsin inhibitors for treating microglia-mediated neuron loss in the central nervous system
  • Cathepsin inhibitors for treating microglia-mediated neuron loss in the central nervous system
  • Cathepsin inhibitors for treating microglia-mediated neuron loss in the central nervous system

Examples

Experimental program
Comparison scheme
Effect test

Embodiment approach

[0079] I. the present invention preferably uses certain compounds shown in formula (I) in the maximum range listed in the summary of the invention, for example:

[0080] (A) A group of preferred compounds used in the present invention are as follows:

[0081] R 1 is cycloalkylalkyl, phenylalkyl, or pyridylalkyl or aralkyl, wherein any aromatic ring or aromatic ring is optionally substituted by 1 or 2 substituents selected from the group consisting of halogen, lower Alkyl, CF 3 , lower alkoxy, or OCF 3 ;

[0082] R 3 is H or phenyl optionally substituted by 1 or 2 substituents selected from the group consisting of halogen, lower alkyl, CF 3 , lower alkoxy, or OCF 3 .

[0083] (B) In another preferred compound used in the present invention,

[0084] R 1 is alkyl, cycloalkylalkyl, phenylalkyl, or pyridylalkyl or aralkyl, wherein any aromatic ring or aromatic ring is optionally replaced by 1 or 2 substituents selected from the following group Substitution: halogen, lower...

Embodiment 1

[0122] N-(1-cyanocyclopropyl)-3-pyridin-3-ylmethylsulfonyl-2(R)-(2,2,2-trifluoro-1(S)-4-fluorophenylethylamine ) Synthesis of Propionamide

[0123]

[0124] step 1

[0125] At 0°C, in a nitrogen atmosphere, in 2(R)-[2,2,2-trifluoro-1(S)-(4-fluorophenyl)ethylamino]-3-trityl-sulfur Alkyl (sulfanyl) propionic acid (539mg, 1mmol, 90% de value, calculated by the purity of the trifluoromethyl group) CH 2 Cl 2 Trifluoroacetic acid (0.4 mL, 4 mmol) and triethylsilane (0.4 mL, 2 mmol) were added to the solution. The reaction mixture was stirred at room temperature for 2 h. The solvent was removed under reduced pressure and the residue was dissolved with 1N NaOH (12 mL). The aqueous layer was washed with hexane, and dioxane (12 mL) was added to the alkaline solution, P(CH 2 CH 2 COOH) 3 , HCl (28mg, 0.1mmol) and 3-chloromethyl-pyridine (196mg, 1.2mmol), the reaction mixture was stirred at room temperature for 2h. Dioxane was removed under reduced pressure and the residue was...

Embodiment 2

[0131] N-(1-cyanocyclopropyl)-2(R)-[2,2,2-trifluoro-1(S)-(2,4-difluoro-phenyl)ethyl-amino]-3 -Synthesis of (cyclopropylmethylsulfonyl) propionamide (compound 43)

[0132]

[0133] step 1

[0134] 2,4-Difluorobenzaldehyde (1.1 mL, 10.0 mmol) and (trifluoromethyl)trimethylsilane (1.77 mL, 12.0 mmol) were dissolved in THF (25 mL), cooled to 0°C. A solution of 1M TBAF in THF (76 μL, 76 μmol) was added to the above mixture, and the reaction mixture was warmed to room temperature. After 3.25 h, 2.5M HCl (25 mL) was added. After the reaction was stirred for 1 h, it was extracted with ether, and the organic layer was washed with brine and washed with Na 2 SO 4 dry. A racemic mixture of 2,2,2-trifluoro-1-(2,4-difluoro-phenyl)ethanol (2.5 g) was obtained after removal of the solvent under reduced pressure.

[0135] step 2

[0136] 2,2,2-Trifluoro-1-(2,4-difluorophenyl)ethanol (1.36g, 6.4mmol) was dissolved in dichloromethane (25mL), diisopropylethylamine (DIPEA, 5mL) was added...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The present invention concerns methods of using Cathepsin S inhibitors and compounds of Formula I that are inhibitors of cathepsin S in treating CNS disorders, diseases, and injuries, particularly neurodegenerative conditions. The present invention is directed to pharmaceutical compositions comprising these compounds for treating CNS disorders.

Description

[0001] Cross References to Related Applications [0002] This application claims priority to US Provisional Application No. 61 / 498,486, filed June 17, 2011, the entire contents of which are incorporated herein by reference. [0003] Claims of ownership of inventions made under federally funded research and development [0004] Not applicable [0005] References to Sequence Listings, tables or computer program attachments submitted on CD-ROM [0006] Not applicable technical field [0007] The present invention relates to compounds that are cysteine ​​S inhibitors, said compounds having good brain penetration. Background technique [0008] Cysteine ​​proteases represent a class of peptidases that have a cysteine ​​residue in the catalytic site of the enzyme. Cysteine ​​proteases are associated with the normal degradation and processing of proteins. However, abnormal activity of cysteine ​​proteases, eg due to increased expression or activation, can lead to pathological c...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A01N55/02
CPCA61K9/08A61K47/26A61K31/4406A61K9/2054A61K47/12A61K31/277A61K9/0019A61P25/00A61P25/16A61P25/28A61P43/00A61P9/00
Inventor R·布思
Owner VIROBAY INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products